TY - JOUR
T1 - Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality
T2 - Prospective cohort study
AU - PURE investigators
AU - O'Donnell, Martin
AU - Mente, Andrew
AU - Rangarajan, Sumathy
AU - McQueen, Matthew J.
AU - O'Leary, Neil
AU - Yin, Lu
AU - Liu, Xiaoyun
AU - Swaminathan, Sumathi
AU - Khatib, Rasha
AU - Rosengren, Annika
AU - Ferguson, John
AU - Smyth, Andrew
AU - Lopez-Jaramillo, Patricio
AU - Diaz, Rafael
AU - Avezum, Alvaro
AU - Lanas, Fernando
AU - Ismail, Noorhassim
AU - Yusoff, Khalid
AU - Dans, Antonio
AU - Iqbal, Romaina
AU - Szuba, Andrzej
AU - Mohammadifard, Noushin
AU - Oguz, Atyekin
AU - Yusufali, Afzal Hussein
AU - Alhabib, Khalid F.
AU - Kruger, Iolanthe M.
AU - Yusuf, Rita
AU - Chifamba, Jephat
AU - Yeates, Karen
AU - Dagenais, Gilles
AU - Wielgosz, Andreas
AU - Lear, Scott A.
AU - Teo, Koon
AU - Yusuf, Salim
N1 - Funding Information:
The funders of the study had no role in its design or conduct, in the collection, analysis, or interpretation of the data, or in the writing of the manuscript. The current analyses were supported by funding from the European Research Council (COSIP grant, 640580) and Heart and Stroke Foundation of Ontario. SY is supported by the Mary W Burke endowed chair of the Heart and Stroke Foundation of Ontario. The PURE study is an investigator initiated study that is funded by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Support from CIHR's Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from Astra Zeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GSK), and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. These include Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network, Canadian Institutes of Health Research (Catalyst Grant: eHealth Innovations-grant No: 126524); Chile: Universidad de La Frontera (Internal Registry DI13-PE11); China: National Center for Cardiovascular Diseases; Colombia: Colciencias, grant No:6566- 04-18062; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia grant No 100-IRDC/BIOTEK 16/6/21 (13/2007), grant No 07-05-IFN-BPH 010, Ministry of Higher Education of Malaysia grant No 600-RMI/ LRGS/5/3 (2/2011), Universiti Teknologi MARA, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur Malaysia. CRIM, University Kebangsaan Malaysia; Occupied Palestinian Territory: The United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), occupied Palestinian territory; International Development Research Centre (IDRC), Canada; Peru: National Heart, Lung and Blood Institute (HHSN268200900033C), National Cancer Institute (1P20CA217231), Wellcome (103994/Z/14/Z); Philippines: Philippine Council for Health Research & Development (PCHRD); Poland: Polish Ministry of Science and Higher Education grant No 290/W-PURE/2008/0, Wroclaw Medical University, Wroclaw Medical University, statutory activity Saudi Arabia: Saudi Heart Association, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (Research group No: RG -1436-013); South Africa: The North-West University, SANPAD (SA and Netherlands Programme for Alternative Development), National Research Foundation, Medical Research Council of SA. The SA Sugar Association (SASA), Faculty of Community and Health Sciences (UWC); Sweden: grants from the Swedish state under the Agreement concerning research and education of doctors; the Swedish Heart and Lung Foundation; the Swedish Research Council; the Swedish Council for Health, Working Life and Welfare, King Gustaf V:s and Queen Victoria Freemason's Foundation, AFA Insurance; Tanzania: Pamoja Tunaweza Health Research Centre (Tanzania), Queen's University, Department of Medicine; Turkey: Metabolic Syndrome Society, Astra Zeneca, Turkey; UAE: Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, and Dubai Health Authority, Dubai UAE.
Publisher Copyright:
© 2019 Published by the BMJ Publishing Group Limited.
PY - 2019
Y1 - 2019
N2 - Objective: To evaluate the joint association of sodium and potassium urinary excretion (as surrogate measures of intake) with cardiovascular events and mortality, in the context of current World Health Organization recommendations for daily intake (<2.0 g sodium, >3.5 g potassium) in adults. Design: International prospective cohort study. Setting: 18 high, middle, and low income countries, sampled from urban and rural communities. Participants: 103 570 people who provided morning fasting urine samples. Main outcome measures: Association of estimated 24 hour urinary sodium and potassium excretion (surrogates for intake) with all cause mortality and major cardiovascular events, using multivariable Cox regression. A six category variable for joint sodium and potassium was generated: sodium excretion (low (<3 g/day), moderate (3-5 g/day), and high (>5 g/day) sodium intakes) by potassium excretion (greater/equal or less than median 2.1 g/day). Results: Mean estimated sodium and potassium urinary excretion were 4.93 g/day and 2.12 g/day, respectively. After a median follow-up of 8.2 years, 7884 (6.1%) participants had died or experienced a major cardiovascular event. Increasing urinary sodium excretion was positively associated with increasing potassium excretion (unadjusted r=0.34), and only 0.002% had a concomitant urinary excretion of <2.0 g/day of sodium and >3.5 g/day of potassium. A J-shaped association was observed of sodium excretion and inverse association of potassium excretion with death and cardiovascular events. For joint sodium and potassium excretion categories, the lowest risk of death and cardiovascular events occurred in the group with moderate sodium excretion (3-5 g/day) and higher potassium excretion (21.9% of cohort). Compared with this reference group, the combinations of low potassium with low sodium excretion (hazard ratio 1.23, 1.11 to 1.37; 7.4% of cohort) and low potassium with high sodium excretion (1.21, 1.11 to 1.32; 13.8% of cohort) were associated with the highest risk, followed by low sodium excretion (1.19, 1.02 to 1.38; 3.3% of cohort) and high sodium excretion (1.10, 1.02 to 1.18; 29.6% of cohort) among those with potassium excretion greater than the median. Higher potassium excretion attenuated the increased cardiovascular risk associated with high sodium excretion (P for interaction=0.007). Conclusions: These findings suggest that the simultaneous target of low sodium intake (<2 g/day) with high potassium intake (>3.5 g/day) is extremely uncommon. Combined moderate sodium intake (3-5 g/day) with high potassium intake is associated with the lowest risk of mortality and cardiovascular events.
AB - Objective: To evaluate the joint association of sodium and potassium urinary excretion (as surrogate measures of intake) with cardiovascular events and mortality, in the context of current World Health Organization recommendations for daily intake (<2.0 g sodium, >3.5 g potassium) in adults. Design: International prospective cohort study. Setting: 18 high, middle, and low income countries, sampled from urban and rural communities. Participants: 103 570 people who provided morning fasting urine samples. Main outcome measures: Association of estimated 24 hour urinary sodium and potassium excretion (surrogates for intake) with all cause mortality and major cardiovascular events, using multivariable Cox regression. A six category variable for joint sodium and potassium was generated: sodium excretion (low (<3 g/day), moderate (3-5 g/day), and high (>5 g/day) sodium intakes) by potassium excretion (greater/equal or less than median 2.1 g/day). Results: Mean estimated sodium and potassium urinary excretion were 4.93 g/day and 2.12 g/day, respectively. After a median follow-up of 8.2 years, 7884 (6.1%) participants had died or experienced a major cardiovascular event. Increasing urinary sodium excretion was positively associated with increasing potassium excretion (unadjusted r=0.34), and only 0.002% had a concomitant urinary excretion of <2.0 g/day of sodium and >3.5 g/day of potassium. A J-shaped association was observed of sodium excretion and inverse association of potassium excretion with death and cardiovascular events. For joint sodium and potassium excretion categories, the lowest risk of death and cardiovascular events occurred in the group with moderate sodium excretion (3-5 g/day) and higher potassium excretion (21.9% of cohort). Compared with this reference group, the combinations of low potassium with low sodium excretion (hazard ratio 1.23, 1.11 to 1.37; 7.4% of cohort) and low potassium with high sodium excretion (1.21, 1.11 to 1.32; 13.8% of cohort) were associated with the highest risk, followed by low sodium excretion (1.19, 1.02 to 1.38; 3.3% of cohort) and high sodium excretion (1.10, 1.02 to 1.18; 29.6% of cohort) among those with potassium excretion greater than the median. Higher potassium excretion attenuated the increased cardiovascular risk associated with high sodium excretion (P for interaction=0.007). Conclusions: These findings suggest that the simultaneous target of low sodium intake (<2 g/day) with high potassium intake (>3.5 g/day) is extremely uncommon. Combined moderate sodium intake (3-5 g/day) with high potassium intake is associated with the lowest risk of mortality and cardiovascular events.
UR - http://www.scopus.com/inward/record.url?scp=85062856691&partnerID=8YFLogxK
U2 - 10.1136/bmj.l772
DO - 10.1136/bmj.l772
M3 - Article
C2 - 30867146
AN - SCOPUS:85062856691
SN - 0959-8146
VL - 364
JO - The BMJ
JF - The BMJ
M1 - l772
ER -